Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.